X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (264) 264
hematology (156) 156
female (155) 155
male (154) 154
middle aged (152) 152
adult (147) 147
aged (143) 143
prognosis (101) 101
aged, 80 and over (100) 100
oncology (89) 89
leukemia, myeloid, acute - genetics (86) 86
beer (83) 83
biochemistry (83) 83
chemistry (83) 83
compositions or test papers therefor (83) 83
condition-responsive control in microbiological orenzymological processes (83) 83
enzymology (83) 83
measuring or testing processes involving enzymes, nucleicacids or microorganisms (83) 83
metallurgy (83) 83
microbiology (83) 83
mutation or genetic engineering (83) 83
processes of preparing such compositions (83) 83
spirits (83) 83
vinegar (83) 83
wine (83) 83
acute myeloid-leukemia (74) 74
mutation (74) 74
physics (70) 70
adolescent (61) 61
investigating or analysing materials by determining theirchemical or physical properties (61) 61
measuring (61) 61
testing (61) 61
cytogenetics (56) 56
genetics & heredity (56) 56
acute myelogenous leukemia (54) 54
karyotyping (51) 51
minimal residual disease (50) 50
aml (48) 48
chromosome aberrations (46) 46
leukemia (44) 44
young adult (44) 44
in situ hybridization, fluorescence (42) 42
acute disease (41) 41
acute myeloid leukemia (37) 37
leukemia, myeloid - genetics (35) 35
translocation, genetic (33) 33
mutations (32) 32
polymerase chain reaction (32) 32
cohort studies (30) 30
hemic and lymphatic diseases (30) 30
abridged index medicus (29) 29
cancer (29) 29
classification (29) 29
leukemia, myeloid, acute - diagnosis (29) 29
gene (28) 28
genetic aspects (28) 28
immunophenotyping (28) 28
internal tandem duplication (28) 28
nuclear proteins - genetics (28) 28
fms-like tyrosine kinase 3 - genetics (27) 27
leukemia, myeloid, acute - pathology (26) 26
myelodysplastic syndrome (26) 26
myelodysplastic syndromes - genetics (26) 26
survival analysis (26) 26
diagnosis (25) 25
acute lymphoblastic-leukemia (24) 24
dna-binding proteins - genetics (24) 24
expression (24) 24
oncogene proteins, fusion - genetics (24) 24
recurrence (24) 24
acute promyelocytic leukemia (23) 23
analysis (23) 23
biomarkers, tumor - genetics (23) 23
gene expression profiling (23) 23
leukemia, myeloid, acute - mortality (23) 23
myeloproliferative disorders - genetics (22) 22
reverse transcriptase polymerase chain reaction (22) 22
gene expression (21) 21
hematology, oncology and palliative medicine (21) 21
disease-free survival (20) 20
prognostic-significance (20) 20
survival rate (20) 20
chromosome banding (19) 19
core binding factor alpha 2 subunit - genetics (19) 19
dna mutational analysis (19) 19
genetic research (19) 19
mutation - genetics (19) 19
follow-up studies (18) 18
janus kinase 2 - genetics (18) 18
myelodysplastic syndromes (18) 18
animals (17) 17
flow cytometry (17) 17
multiparameter flow cytometry (17) 17
neoplasm proteins - genetics (17) 17
proto-oncogene proteins - genetics (17) 17
research (17) 17
child (16) 16
cytogenetic analysis (16) 16
flow cytometry - methods (16) 16
normal cytogenetics (16) 16
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of clinical oncology, ISSN 1527-7755, 2014, Volume 32, Issue 5, pp. 415 - 423
Purpose Deep molecular response (MR4.5) defines a subgroup of patients with chronic myeloid leukemia (CML) who may stay in unmaintained remission after... 
MESYLATE | INTERFERON-ALPHA | THERAPY | CHRONIC-PHASE | ONCOLOGY | RECOMMENDATIONS | CLINICAL-TRIALS | 800 MG | END-POINTS | EUROPEAN-LEUKEMIANET | CHRONIC MYELOID-LEUKEMIA | Piperazines - administration & dosage | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Young Adult | Benzamides - administration & dosage | Time Factors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Aged, 80 and over | Adult | Female | Benzamides - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Pyrimidines - administration & dosage | Risk Factors | Proportional Hazards Models | Treatment Outcome | Imatinib Mesylate | Piperazines - adverse effects | Remission Induction | Cytarabine - administration & dosage | Disease Progression | Interferon-alpha - administration & dosage | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Aged | Fusion Proteins, bcr-abl - metabolism
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2011, Volume 364, Issue 24, pp. 2305 - 2315
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2013, Volume 31, Issue 19, pp. 2428 - 2436
Journal Article
Nature genetics, ISSN 1546-1718, 2012, Volume 45, Issue 1, pp. 18 - 24
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 2008, Volume 105, Issue 10, pp. 3945 - 3950
Journal Article
Annals of Hematology, ISSN 0939-5555, 1/2014, Volume 93, Issue 1, pp. 71 - 80
... Kalmanti & Susanne Saussele & Michael Lauseker & Ulrike Proetel & Martin C. Müller & Benjamin Hanfstein & Annette Schreiber & Alice Fabarius & Markus Pfirrmann... 
Medicine & Public Health | Hematology | Young adults and adolescents | Oncology | Accelerated phase | Blast crisis | Chronic myeloid leukemia | DIAGNOSIS | ADULTS | CANCER | TYROSINE KINASE INHIBITORS | Chronicmyeloid leukemia | THERAPY | RECOMMENDATIONS | ADOLESCENTS | CLINICAL-TRIALS | IMATINIB | HEMATOLOGY | AGE | Piperazines - administration & dosage | Age Factors | Follow-Up Studies | Humans | Middle Aged | Male | RNA, Neoplasm - blood | Young Adult | Benzamides - administration & dosage | Benzamides - therapeutic use | Karnofsky Performance Status | Fusion Proteins, bcr-abl - blood | Splenomegaly - etiology | Adult | Female | Randomized Controlled Trials as Topic - statistics & numerical data | Pyrimidines - administration & dosage | Leukemia, Myeloid, Chronic-Phase - blood | Leukemia, Myeloid, Chronic-Phase - drug therapy | Risk Factors | Kaplan-Meier Estimate | Treatment Outcome | Piperazines - therapeutic use | Imatinib Mesylate | Cytarabine - administration & dosage | Interferon-alpha - administration & dosage | Leukemia, Myeloid, Chronic-Phase - mortality | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | RNA, Messenger - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Adolescent | Aged | Leukemia, Myeloid, Chronic-Phase - genetics | Hemoglobin | Research | Analysis | Oncology, Experimental | Cancer | Original
Journal Article
Journal Article
Journal Article
Nature Communications, ISSN 2041-1723, 04/2015, Volume 6, Issue 1, p. 6691
Journal Article